Status:
COMPLETED
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Lead Sponsor:
Pfizer
Conditions:
Chronic Myeloid Leukaemia
Eligibility:
All Genders
Brief Summary
The objectives of this study are to describe patient demographics, clinical and disease characteristics and treatment patterns of Chronic Lymphoid Leukaemia (CML) in Hungary. The primary endpoint of ...
Eligibility Criteria
Inclusion
- Female and male patients diagnosed with chronic myeloid leukemia
- Patients receiving tyrosine kinase inhibitor therapy under the terms of the current marketing authorization
Exclusion
- Patients receiving TKI for non-CML diagnoses
Key Trial Info
Start Date :
November 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
1484 Patients enrolled
Trial Details
Trial ID
NCT05286528
Start Date
November 18 2020
End Date
January 31 2022
Last Update
October 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Budapest, Hungary